We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go: Stretch investment: Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Studio Pictures Ltd is a UK-based film and TV production company founded by producers Adam Rolston and David Braithwaite in 2019. Specializing in creating high-quality British entertainment content, the company focuses on adapting books to screen and telling unique true-life stories that entertain and inspire both domestic and international audiences. With successful productions like "A Street Cat Named Bob," the company is building a strong brand and reputation in the industry. Studio Pictures has access to top creative talent and collaborates with major studios like Warner Bros, Sony Pictures, Lionsgate, and Studio Canal. The company is located at Twickenham Studios in Richmond, UK.
days to go: 30 investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Urban is a wellness app that allows customers to book massages, beauty treatments, personal training and more at the customer's doorstep in 60 minutes. The company's practitioners are already operating in London, Paris, Manchester and Birmingham covering all aspects of wellness, from massage to mindfulness and beyond. Urban has delivered over 650,000 appointments till date, witnessed £43 million in cumulative sales value since August 2018, onboarded 3,800 partner practitioners, and saw 7,300+ reviews on Apple app store with an average rating of 4.8/5 stars. It will use the investment to drive towards Operating Expense (OpEx) profitability by the end of Q1 2021, reach EBITDA positive by the end of 2021, and scale into new markets through remote expansion.
days to go: Expired investment: £5,877,517
YurOn is a video platform that cultivates authentic interaction between prominent personalities and their fans. The portal allows people from different walks of life–drag queens, mountaineers, activists–thirty seconds to ignite a conversation, start an Ask Me Anything or co-create a skit. YurOn shuns away filters, anonymous commenting, vanity metrics or validation-driven algorithms and endeavours to bring to the public an unadulterated conversation between stars and their fans. The portal soft-launched in Q2 of 2020 and has seen over 5000 downloads, 2000 active users, and 32% of users retaining over a month. The company will use 80% of the investment to grow its tech team and cloud infrastructure, and 20% towards marketing and partnerships to accelerate growth.

Pitch Rated

46%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £222,110
Feed is a platform that automates digital advertising for musicians and creators by enabling them to grow an audience and build their businesses. The creator needs to connect their social media accounts to the Feed portal and set a budget. The portal will then create ads that reach new people and convert engaged audiences into loyal fans over time. The company asserts that existing ad generation platforms are too complex, time-consuming and expensive for creators. Feed argues that its portal caters to a variety of budgets, requires no marketing knowledge and takes minutes to get started. The beta platform is integrated with Facebook's & Instagram's ad network and has 500 creators on board. The company will use the investment to launch the paid version of Feed in Q4 2020. 

Pitch Rated

47%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £146,117
GymBuddy is an online platform that enables consumers to find, book, and attend a gym location, services, or products offered and operated by fitness studios, gyms, trainers, venues, or other third parties. Users can easily, through filtered searches on the app, view descriptions, and contact information of specialists within the fitness industry such as personal trainers, nutritionists, and physiotherapists. The UK fitness industry alone is currently worth over £5 billion. Based on recent statistics, the average gym membership in the UK costs members £40 a month, which often ties them into lengthy contracts. The GymBuddy app will enter the Health & Fitness club sector as a multi-gym membership feature that gives users access to gyms and various fitness plans, without the need for bricks-and-mortar locations under its brand. The company is seeking an investment of £400,000 to expand its brand identity and bring more users to its ecosystem to generate profits.

Pitch Rated

30%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Thalamos is a software solution for completing the Mental Health Act (MHA) forms digitally, across any device. It aims to help those with acute mental illness access care quickly reducing treatment time from 7 days to 27 hours. The company delivers SaaS (Software-as-a-Service) to National Health Service (NHS) Trusts, local authorities and private mental healthcare providers. It also works directly with the UK healthcare regulator, The Care Quality Commission (CQC). Thalamos has over £500,000 of investment raised till date. Pre Covid-19, the company was already working with the CQC and supported them in safely submitting their statutory forms to hospitals across the country. Over 75% of NHS Trusts have received Thalamos' MHA forms in the last 60 days. The company will use 48% of the investment for product development, 20% for customer on-boarding, 16% for business development, and 16% as working capital.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £290,278
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph